

ImmunoCAP ISAC assay helps solve **puzzling allergies**

When symptoms indicate multi-sensitization or broad cross-reactivity

A multiplex test may reduce time to diagnosis and save costs^{1*}

It can provide a quick and comprehensive sensitization profile¹

When symptoms are inconsistent with previous test results

You can decipher inconsistencies with a broad sensitization profile¹

When many tests results must be derived from a limited volume of blood

You can get 112 test results in one go and from only 30 µl serum²

and provides **unparalleled answers** for improved patient management

Provides accurate diagnosis

Differentiates between cross-reactive and specific sensitizations

Helps rule in or rule out IgE-mediated allergies

Assesses and predicts risk

Helps evaluate risk for systemic reactions in food allergy

An aid to predict development of respiratory disease

Guides patient management^{}**

An aid in deciding on avoidance strategies

Helps guide towards allergen immunotherapy

CLINICALLY PROVEN

*Referred as the 'bottom-up' approach by EAACI

**ImmunoCAP ISAC assay results are semi-quantitative. When quantitative results are needed, ImmunoCAP sIgE may add value.

thermo scientific



The updated ImmunoCAP ISAC assay helps to give **unparalleled answers** to puzzling allergies

Clinically relevant

Powerful combination of assay performance and documented relevance of allergens.¹
Interpretation support to aid diagnosis of allergy.

Clinically validated

Evaluated in over 260 peer-reviewed publications.³
Robust performance, good reproducibility and low variation demonstrated in a global validation study.⁴

Clinically proven

Over 12 years of experience from clinical practice.

References

1. Matricardi et al. 27 (2016) PAI (suppl23): 1–250. 2. DFU ImmunoCAP ISAC E112i. 52-5710-EN/01. 3. Thermo Fisher Scientific compiled list of publications. 20190520.
4. Van Hage, M. et al. Performance evaluation of ImmunoCAP ISAC 112: a multi-site study. Journal: Clin Chem Lab Med 2017; 55(4): 571–577.

Find out more about ImmunoCAP ISAC assay at:
thermoscientific.com/phadia

ThermoFisher
SCIENTIFIC

For use in clinical laboratories. Phadia AB is the manufacturer and a legal entity of Thermo Fisher Scientific. Availability of EIA and ImmunoCAP assays varies per country. © 2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. **100501.AL.GB1.EN.v1.19**

thermoscientific



ImmunoCAP™
ISAC

**Puzzling allergies?
Unparalleled answers.**

ImmunoCAP™ ISAC assay.
Clinically relevant. Clinically validated. Clinically proven.

ThermoFisher
SCIENTIFIC

ImmunoCAP ISAC: More than just a multiplex assay



Finding the real causes of an allergic reaction may require several pieces of information to fit together.

This is especially true when symptoms and case history are inconsistent, the patient is multi-sensitized or shows unsatisfactory response to the treatment.

In these puzzling cases, making the correct diagnosis may be both time-consuming and problematic.

The updated ImmunoCAP™ ISAC assay is the clinically proven solution for investigating puzzling allergies.

It is highly efficient when the patient's many sensitizations are best tested simultaneously using a panel of allergen components.¹


**CLINICALLY
VALIDATED**

ImmunoCAP ISAC assay has the power to support the diagnosis of complex, cross-reactive and combination allergies

A relevant combination of documented allergens¹

ImmunoCAP ISAC assay consists of 112 allergen components from 48 different allergen sources, thoroughly selected based on evidence in clinical literature, for their potential to improve allergy diagnosis, assess risk for systemic reactions and guide patient management.^{1,2}

**CLINICALLY
RELEVANT**




Test results are processed by an interpretation aid* to support clinical decision-making



Visualized results



Interpreted results



1. Summary of positive IgE results

Mainly species-specific food components			
Cashew nut	Ana o 3	Storage protein, 2S albumin	1,7 ISU-E
Brazil nut	Ber e 1	Storage protein, 2S albumin	10 ISU-E
Hazelnut	Cor a 14	Storage protein, 2S albumin	5,3 ISU-E

Cross-reactive components

PR-10 protein			
Birch	Bet v 1	PR-10 protein	9,9 ISU-E
Alder	Aln g 1	PR-10 protein	0,8 ISU-E
Hazelnut	Cor a 1.0401	PR-10 protein	2,4 ISU-E
Peach	Pru p 1	PR-10 protein	0,4 ISU-E

Phadia Xplain

SUMMARY COMMENTS
This patient has IgE to both species-specific and cross-reactive components. IgE to brazil nut Ber e 1 is associated with risk of systemic allergic reactions. In general, the higher the sIgE level the greater the likelihood of allergic symptoms.

FOOD COMPONENTS (mainly species-specific)
IgE to brazil nut detected.
Nuts, Seeds & Legumes: IgE to the storage protein(s) brazil nut Ber e 1 is associated with risk of systemic allergic reactions. Many storage proteins are heat and digestion stable and associated with allergic reactions both to cooked and uncooked food.

AEROALLERGEN COMPONENTS (mainly species-specific)
IgE to birch, timothy, cat, horse and bermuda grass detected (listed in descending IgE concentration).
Pollen: IgE to timothy components may cross-react with similar proteins in other grasses. IgE to bermuda grass Cyn d 1 and timothy grass Phi p 1 may cross-react. IgE to birch Bet v 1 may cross-react with pollen of related trees and plant foods containing PR-10 proteins (e.g. Rosaceae fruits, peanut, soy, hazelnut, carrot, kiwi or celery).
Animals: Fel d 1 is the main specific cat allergen. Equ c 1 is the main horse allergen. IgE to horse Equ c 1, cat Fel d 4 and mouse Mus m 1 may cross-react.

FOOD-INHALATION CROSS-REACTIVE COMPONENTS
IgE to food-inhalation cross reactive components detected.
PR-10: IgE to hazelnut Cor a 1.0401 and peach Pru p 1 is associated with local allergic reactions (typically OAS) in patients with pollen-food-syndrome caused by sensitization to pollen from birch or related trees. Most PR-10 proteins are sensitive to heat and digestion and cooked food is often tolerated.

ImmunoCAP ISAC assay results are presented in a structured report and provide a detailed overview of a patient's primary and cross-reactive sensitizations as well as the clinical implication. This can help you make better decisions on patient management.

* Phadia™ Xplain. Based on results and findings from peer-reviewed literature.